Elkedonia appoints industry veteran Pierre d’Epenoux, former CEO of ImCheck Therapeutics, as Independent Chairman to strengthen its Board of Directors. This leadership addition supports the company’s growth as it advances its innovative, non-hallucinogenic neuroplastogens targeting the ELK1 protein for major depressive disorder. With extensive expertise in biotech-pharma partnerships, Mr. d’Epenoux will guide Elkedonia through its [...]

Delphine Charvin, CEO and co-founder of Elkedonia, was the guest of Sandra Gandoin on BFM Business, on July 15 2025. She discussed her company’s new antidepressant treatment approach, which is different from what is available today, aiming to meet the needs of patients who currently have no effective therapeutic solutions. On Good Morning Business.

We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly.                                                                                                                 

A new report studied depression levels across Europe and in older and younger individuals, with the outlook for France looking particularly poor. France may have had the highest pre-pandemic depression level among European countries, according to a new analysis of a 2019 health survey across the continent.